Merck KGaA agrees to acquire Silence Therapeutics for $20 per ADS

Bitget2026/10/19 12:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Merck KGaA agreed to acquire Silence Therapeutics for $20 per ADS in cash, valuing its equity at approximately $1.3 billion.
Enterprise value is $1.1 billion; consideration represents an 82% premium to the 30-day volume-weighted average of $10.99 as of October 16, 2026.
The acquisition adds Divesiran, a Phase 3-ready investigational siRNA therapy for polycythemia vera, strengthening the buyer’s rare-disease pipeline.
Closing is expected in the first quarter of 2027, subject to regulatory and shareholder approvals; new debt will fund the acquisition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief via Business Wire (Ref. ID: 202610190800BIZWIRE_USPR_____20261019_BW777870) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Merck KGaA agrees to acquire Silence Therapeutics for $20 per ADS

You may also like

Crypto prices